AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Lipocine Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0029L1Y76
1.44▼ 0.02 (-1.37%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
1.46
Day's Range
1.41 – 1.48
52-Week Range
1.40 – 12.39
Volume
216.0K
Avg Volume
3.8M
Share Statistics
Shares Outstanding
Employees
14
Exchange
XNAS
Listed
2012-06-05
Share count as of August 3, 2026

Lipocine Inc. (LPCN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Lipocine Inc. (LPCN)
What is Lipocine Inc.'s Market Cap?
Lipocine Inc.'s Market Cap is $11.9M, based on as-reported figures from SEC (XBRL) filings.
What is Lipocine Inc.'s Price / Sales?
Lipocine Inc.'s Price / Sales is 7.6×, based on as-reported figures from SEC (XBRL) filings.
What is Lipocine Inc.'s Revenue (TTM)?
Lipocine Inc.'s Revenue (TTM) is $1.6M, based on as-reported figures from SEC (XBRL) filings.
What is Lipocine Inc.'s Net Income (TTM)?
Lipocine Inc.'s Net Income (TTM) is -$11.9M, based on as-reported figures from SEC (XBRL) filings.
What is Lipocine Inc.'s EBITDA?
Lipocine Inc.'s EBITDA is -$12.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lipocine Inc.'s Diluted EPS (TTM)?
Lipocine Inc.'s Diluted EPS (TTM) is -1.44, based on as-reported figures from SEC (XBRL) filings.
What is Lipocine Inc.'s EBITDA Margin?
Lipocine Inc.'s EBITDA Margin is -797.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LPCNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
License revenue——
Royalty revenue recognised
Total revenues
YoY growth-69.5%+27.2%-67.2%—
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
% of revenue1595.1%3324.1%319.6%3033.5%
Operating loss
% of revenue-1495.1%-3224.1%-219.6%-2933.5%
Other income:
Interest and Dividend Income (Non-Bank)
Total other income
Loss before income tax expense
Income tax expense—
Net loss attributable to common shareholders
% of revenue-1379.6%-3075.4%-206.9%-2781.5%
Earnings Per Share (Basic)
Earnings Per Share (Diluted)